Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 108

Sort by

Sort Order Select

Journal Articles

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

Blood blood.2024025454.

https://doi.org/10.1182/blood.2024025454

Published: 2024

Includes: Supplemental data

Journal Articles

Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas

Stephen J. Schuster, Ling-Yuh Huw, Christopher R. Bolen, Victor Maximov, Andrew G. Polson, Katerina Hatzi, Elisabeth A. Lasater, Sarit E. Assouline, Nancy L. Bartlett, L. Elizabeth Budde, Matthew J. Matasar, Hartmut Koeppen, Emily C. Piccione, Deanna Wilson, Michael C. Wei, Shen Yin, Elicia Penuel

Blood (2024) 143 (9): 822–832.

https://doi.org/10.1182/blood.2023022348

Published: 2024

Includes: Supplemental data

Journal Articles

Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study

Blood (2022) 140 (Supplement 1): 1297–1300.

https://doi.org/10.1182/blood-2022-157559

Published: 2022

Journal Articles

Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study

Blood (2022) 140 (Supplement 1): 3753–3755.

https://doi.org/10.1182/blood-2022-157729

Published: 2022

Journal Articles

Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2

Blood (2022) 140 (Supplement 1): 1756–1758.

https://doi.org/10.1182/blood-2022-156382

Published: 2022

Journal Articles

Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 1065–1067.

https://doi.org/10.1182/blood-2022-165699

Published: 2022

Journal Articles

Characterization of a Large Cohort of Patients with Nodal Marginal Zone Lymphoma Shows Prolonged Survival, Time-to-Treatment, and Time-to-Transformation

Blood (2022) 140 (Supplement 1): 9380–9382.

https://doi.org/10.1182/blood-2022-156383

Published: 2022

Journal Articles

Pooled Safety Analysis from Phase I-III Studies for Patients with Hematological Malignancies Treated with the PI3K Inhibitor Copanlisib

Pier Luigi Zinzani, Muhit Özcan, Marcelo Capra, Armando Santoro, Panayiotis Panayiotidis, Krimo Bouabdallah, Wojciech Jurczak, Charles Phelps, Florian JR Hiemeyer, Lidia Mongay Soler, Jose Garcia-Vargas, Barrett H. Childs, Georg Lenz, Matthew J. Matasar, Martin Dreyling

Blood (2022) 140 (Supplement 1): 6470–6473.

https://doi.org/10.1182/blood-2022-167368

Published: 2022

Journal Articles

Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies

Blood (2022) 140 (Supplement 1): 6436–6438.

https://doi.org/10.1182/blood-2022-163235

Published: 2022

Journal Articles

Vitalize Trial: A Phase 2b, Open-Label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of the Novel Immunotherapeutic, Maveropepimut-S, and Pembrolizumab with and without Intermittent Low-Dose Cyclophosphamide, in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Matthew J. Matasar, Eric Lee, Sophie Leitch, Melhem Solh, Jennifer Teti, Kabir Mody, Stephan Fiset, Jeremy Graff

Blood (2022) 140 (Supplement 1): 12073–12074.

https://doi.org/10.1182/blood-2022-159000

Published: 2022

Journal Articles

Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study

Nancy L. Bartlett, Laurie H. Sehn, Matthew J. Matasar, Stephen J. Schuster, Sarit Assouline, Pratyush Giri, John Kuruvilla, Miguel Canales, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta J. Nastoupil, Michael C. Wei, Shen Yin, Iris To, Huang Huang, Juliana Min, Elicia Penuel, L. Elizabeth Budde

Blood (2022) 140 (Supplement 1): 1467–1470.

https://doi.org/10.1182/blood-2022-157691

Published: 2022

Journal Articles

Closing the Gap: Implementation of a Novel Interactive Virtual Tumor Board to Improve Expert Knowledge Sharing in Malignant Hematology

Jordan Ciuro, Elizabeth Henry, Nadine Housri, Rahul Banerjee, Elizabeth A Brem, Taylor Brooks, Ben A. Derman, Brian T. Hill, Craig C Hofmeister, Matthew A. Lunning, Matthew J. Matasar, Tycel J. Phillips, Sarah C. Rutherford, Saurabh Zanwar, Lauren E Lee

Blood (2022) 140 (Supplement 1): 13180–13181.

https://doi.org/10.1182/blood-2022-167959

Published: 2022

Journal Articles

LymphGen Classification of Diffuse Large B-Cell Lymphoma in a Cohort of Adolescent and Young Adult (AYA) Patients

Angelo Cabal, Menglei Zhu, Manik Uppal, Erel Joffe, Connie Lee Batlevi, Matthew J. Matasar, Michelle Okwali, Ahmet Dogan, Andrew D. Zelenetz, Gilles Salles, Niloufer Khan

Blood (2022) 140 (Supplement 1): 6392–6393.

https://doi.org/10.1182/blood-2022-162418

Published: 2022

Journal Articles

Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study

Laurie H. Sehn, Mark Hertzberg, Stephen Opat, Alex F. Herrera, Sarit Assouline, Christopher R. Flowers, Tae Min Kim, Andrew K. McMillan, Muhit Özcan, Violaine Safar, Gilles Salles, Jamie Hirata, Annie Yang, Lisa Musick, Matthew J. Matasar

Blood (2022) 140 (Supplement 1): 9464–9467.

https://doi.org/10.1182/blood-2022-157679

Published: 2022

Journal Articles

Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Blood (2022) 140 (Supplement 1): 9286–9288.

https://doi.org/10.1182/blood-2022-160206

Published: 2022

Journal Articles

Molecular Profiling across Lymphoma Subtypes Using MSK-Impact Next Generation Sequencing

Blood (2022) 140 (Supplement 1): 9251–9253.

https://doi.org/10.1182/blood-2022-158783

Published: 2022

Journal Articles

Population Pharmacokinetics and Exposure-Response Analyses from Phase I-III Studies Support Copanlisib Dose Selection in Relapsed Indolent Non-Hodgkin Lymphoma

Jonathan Moss, Dirk Garmann, Rupert Austin, Florian Hiemeyer, Matthew J. Matasar, Pier Luigi Zinzani, Vita Beckert, Lidia Mongay Soler, Barrett H. Childs, Peter N. Morcos

Blood (2022) 140 (Supplement 1): 3629–3631.

https://doi.org/10.1182/blood-2022-162819

Published: 2022

Journal Articles

Clinical Outcomes and CNS Relapse Risk in Patients with Primary Cutaneous DLBCL, Leg Type Treated in the Rituximab Era: Long-Term Follow-up of a Single-Center Experience

Blood (2021) 138 (Supplement 1): 2513.

https://doi.org/10.1182/blood-2021-151994

Published: 2021

Journal Articles

Impact of Choice of Platinum-Based Salvage Therapy on CNS Relapse in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Blood (2021) 138 (Supplement 1): 2529.

https://doi.org/10.1182/blood-2021-147527

Published: 2021

Journal Articles

Favorable Outcomes of Patients with Limited-Stage Ocular Adnexal DLBCL Treated in the Rituximab Era: Long-Term Follow-up of a Single Center Experience

Blood (2021) 138 (Supplement 1): 4578.

https://doi.org/10.1182/blood-2021-153171

Published: 2021

NARROW

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas

Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study

Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study

Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2

Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Characterization of a Large Cohort of Patients with Nodal Marginal Zone Lymphoma Shows Prolonged Survival, Time-to-Treatment, and Time-to-Transformation

Pooled Safety Analysis from Phase I-III Studies for Patients with Hematological Malignancies Treated with the PI3K Inhibitor Copanlisib

Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies

Vitalize Trial: A Phase 2b, Open-Label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of the Novel Immunotherapeutic, Maveropepimut-S, and Pembrolizumab with and without Intermittent Low-Dose Cyclophosphamide, in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study

Closing the Gap: Implementation of a Novel Interactive Virtual Tumor Board to Improve Expert Knowledge Sharing in Malignant Hematology

LymphGen Classification of Diffuse Large B-Cell Lymphoma in a Cohort of Adolescent and Young Adult (AYA) Patients

Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study

Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Molecular Profiling across Lymphoma Subtypes Using MSK-Impact Next Generation Sequencing

Population Pharmacokinetics and Exposure-Response Analyses from Phase I-III Studies Support Copanlisib Dose Selection in Relapsed Indolent Non-Hodgkin Lymphoma

Clinical Outcomes and CNS Relapse Risk in Patients with Primary Cutaneous DLBCL, Leg Type Treated in the Rituximab Era: Long-Term Follow-up of a Single-Center Experience

Impact of Choice of Platinum-Based Salvage Therapy on CNS Relapse in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Favorable Outcomes of Patients with Limited-Stage Ocular Adnexal DLBCL Treated in the Rituximab Era: Long-Term Follow-up of a Single Center Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only